Billed as Withings’ most advanced device to date, the ScanWatch uses two detection methods to identify if users have an irregular heart rhythm (AFib) or if their heart rhythm is slow, high or normal. The first is through users taking an electroECG on-demand when they feel symptoms like palpitations.
“ScanWatch is our most ambitious medical tracker and purposely designed to detect the early presence of AFib and sleep apnea – two related issues that are extremely common yet largely undiagnosed, despite their known impact on multiple health conditions,” said Mathieu Letombe, CEO of Withings. “Worn throughout the day and night, ScanWatch provides an early warning system, collecting and sharing critical health data with users and their physicians.”
When symptoms aren’t present, the watch offers a second early detection capability that continuously monitors heart rate through a PPG sensor to alert users of a potential issue and encourages them then to take an ECG.
Sleep apnea affects an estimated 22 million adults in the U.S., with another 80 percent of cases of moderate and severe obstructive sleep apnea undiagnosed, according to the American Sleep Apnea Association.
Withings claims ScanWatch can detect the presence of sleep apnea episodes through a SpO2 sensor. All of the sleep, cardiovascular and activity data collected by ScanWatch is stored in the accompanying Health Mate app and can be shared from there with a physician.
The PMOLED digital display in the center of the watch face is bigger than previous hybrid Withings smartwatches and shows health and sports data such as daily and previous day steps and sleep score as well as calories, distance, and heart rate. You can also scroll through each screen using the watch’s newly designed digital crown.
The digital crown also allows you to launch an ECG record and SPO2 measurement, start workout modes and deactivate/set alarms, while the display shows smartphone notifications, which appear along with a discrete vibration.
The ScanWatch offers 30 days of battery life on a single charge. Pending CE and FDA-clearance, Withings expects it to be available in the U.S. and Europe in the second quarter of this year. Pricing will start at $249/£229 for the 38mm model and $299/£279 for the 42mm model.
With an impressive 30-day battery life, ScanWatch shares the elegant analog look of previous Withings’ hybrid watches with a number of enhanced design elements. It features a larger digital display than previous models as well as improved navigation through a newly created crown dial. It is slated to be available in Europe and the United States in Q2 2020 for €249/£229/$249 (38mm), €299/£279/$299 (42mm), pending CE and FDA-clearance.
CES & Availability
Demonstrations of ScanWatch, which has been honored with three CES Innovation awards, will be available during CES January 7-10, 2020 at the Sands Expo Center, Hall A-D booth #44831.
Pending CE and FDA-clearance, ScanWatch will be available in Europe and the United States in Q2 2020 for €249/£229/$249 (38mm) and for €299/£279/$299 (42mm) at withings.com and Amazon. In addition to the two watch size options, users will be able to select from a variety of color options and select from swappable soft silicone and leather wristbands.